The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
4D MOLECULAR THERAPEUTICS IN | COM | 35104E100 | 54,210,000 | 3,000,000 | SH | SOLE | 3,000,000 | 0 | 0 | |||
ACLARIS THERAPEUTICS INC | COM | 00461U105 | 10,792,619 | 1,040,754 | SH | SOLE | 1,040,754 | 0 | 0 | |||
ADVERUM BIOTECHNOLOGIES INC | COM | 00773U108 | 6,179,131 | 3,886,246 | SH | SOLE | 3,886,246 | 0 | 0 | |||
AEGLEA BIOTHERAPEUTICS INC | COM | 00773J103 | 2,857,621 | 6,343,221 | SH | SOLE | 6,343,221 | 0 | 0 | |||
AFFIMED N V | COM | N01045108 | 854,571 | 1,428,571 | SH | SOLE | 1,428,571 | 0 | 0 | |||
AMBRX BIOPHARMA INC | SPONSORED ADS | 02290A102 | 40,902,442 | 2,484,960 | SH | SOLE | 2,484,960 | 0 | 0 | |||
APPLIED THERAPEUTICS INC | COM | 03828A101 | 7,242,284 | 5,658,034 | SH | SOLE | 5,658,034 | 0 | 0 | |||
AVALO THERAPEUTICS INC | COM NEW | 05338F207 | 444,000 | 1,250,000 | SH | SOLE | 1,250,000 | 0 | 0 | |||
BLACK DIAMOND THERAPEUTICS I | COM | 09203E105 | 1,785,826 | 353,629 | SH | SOLE | 353,629 | 0 | 0 | |||
CABALETTA BIO INC | COM | 12674W109 | 25,474,670 | 1,973,251 | SH | SOLE | 1,973,251 | 0 | 0 | |||
CELCUITY INC | COM | 15102K100 | 23,117,138 | 2,105,386 | SH | SOLE | 2,105,386 | 0 | 0 | |||
COGENT BIOSCIENCES INC | COM | 19240Q201 | 55,460,123 | 4,684,132 | SH | SOLE | 4,684,132 | 0 | 0 | |||
DYNE THERAPEUTICS INC | COM | 26818M108 | 24,456,521 | 2,173,913 | SH | SOLE | 2,173,913 | 0 | 0 | |||
ENLIVEN THERAPEUTICS INC | COM | 29337E102 | 45,516,892 | 2,230,127 | SH | SOLE | 2,230,127 | 0 | 0 | |||
GH RESEARCH PLC | ORDINARY SHARES | G3855L106 | 41,730,688 | 3,517,125 | SH | SOLE | 3,517,125 | 0 | 0 | |||
KALVISTA PHARMACEUTICALS INC | COM | 483497103 | 26,250,003 | 2,916,667 | SH | SOLE | 2,916,667 | 0 | 0 | |||
LYRA THERAPEUTICS INC | COM | 55234L105 | 3,798,339 | 924,170 | SH | SOLE | 924,170 | 0 | 0 | |||
MERUS N V | COM | N5749R100 | 45,451,215 | 1,726,214 | SH | SOLE | 1,726,214 | 0 | 0 | |||
MILESTONE PHARMACEUTICALS IN | COM | 59935V107 | 6,295,114 | 2,208,812 | SH | SOLE | 2,208,812 | 0 | 0 | |||
ORIC PHARMACEUTICALS INC | COM | 68622P109 | 16,628,563 | 2,142,856 | SH | SOLE | 2,142,856 | 0 | 0 | |||
PHARVARIS N V | COM | N69605108 | 20,078,668 | 1,326,200 | SH | SOLE | 1,326,200 | 0 | 0 | |||
PLIANT THERAPEUTICS INC | COM | 729139105 | 5,235,756 | 288,949 | SH | SOLE | 288,949 | 0 | 0 | |||
PRAXIS PRECISION MEDICINES I | COM | 74006W108 | 6,100,072 | 5,304,410 | SH | SOLE | 5,304,410 | 0 | 0 | |||
RALLYBIO CORP | COM | 75120L100 | 1,519,891 | 268,532 | SH | SOLE | 268,532 | 0 | 0 | |||
RHYTHM PHARMACEUTICALS INC | COM | 76243J105 | 17,974,100 | 1,090,000 | SH | SOLE | 1,090,000 | 0 | 0 | |||
SAVARA INC | COM | 805111101 | 20,293,142 | 6,351,531 | SH | SOLE | 6,351,531 | 0 | 0 | |||
TERNS PHARMACEUTICALS INC | COM | 880881107 | 26,012,604 | 2,972,869 | SH | SOLE | 2,972,869 | 0 | 0 | |||
THESEUS PHARMACEUTICALS INC | COM | 88369M101 | 7,184,100 | 770,000 | SH | SOLE | 770,000 | 0 | 0 | |||
TREVI THERAPEUTICS INC | COM | 89532M101 | 8,179,529 | 3,422,397 | SH | SOLE | 3,422,397 | 0 | 0 | |||
VIRIDIAN THERAPEUTICS INC | COM | 92790C104 | 73,335,577 | 3,082,622 | SH | SOLE | 3,082,622 | 0 | 0 |